Whitehawk Therapeutics (WHWK) Cash & Equivalents (2018 - 2025)
Historic Cash & Equivalents for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $162.6 million.
- Whitehawk Therapeutics' Cash & Equivalents rose 43246.88% to $162.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.6 million, marking a year-over-year increase of 43246.88%. This contributed to the annual value of $28.7 million for FY2024, which is 5441.1% down from last year.
- As of Q3 2025, Whitehawk Therapeutics' Cash & Equivalents stood at $162.6 million, which was up 43246.88% from $177.2 million recorded in Q2 2025.
- In the past 5 years, Whitehawk Therapeutics' Cash & Equivalents registered a high of $227.6 million during Q1 2025, and its lowest value of $28.7 million during Q4 2024.
- For the 5-year period, Whitehawk Therapeutics' Cash & Equivalents averaged around $92.8 million, with its median value being $68.2 million (2023).
- In the last 5 years, Whitehawk Therapeutics' Cash & Equivalents crashed by 7381.08% in 2022 and then soared by 43246.88% in 2025.
- Quarter analysis of 5 years shows Whitehawk Therapeutics' Cash & Equivalents stood at $149.0 million in 2021, then plummeted by 73.81% to $39.0 million in 2022, then skyrocketed by 61.17% to $62.9 million in 2023, then crashed by 54.41% to $28.7 million in 2024, then skyrocketed by 467.14% to $162.6 million in 2025.
- Its last three reported values are $162.6 million in Q3 2025, $177.2 million for Q2 2025, and $227.6 million during Q1 2025.